Ziltivekimab is a human monoclonal antibody directed against IL-6. ... cardiovascular death, heart failure hospitalization or urgent heart failure visit.

Ziltivekimab is a human monoclonal antibody directed against IL-6. ... cardiovascular death, heart failure hospitalization or urgent heart failure visit.

11 окт. 2024 г. · Heart attack, stroke, unstable angina pectoris, transient ischemic attack, or heart failure hospitalization, within 30 days prior to screening ( ...

15 окт. 2024 г. · ... Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES) ... Structural heart disease and/or functional heart ...

9 окт. 2024 г. · Modulation of Inflammation in Heart Failure: The Role of Ziltivekimab and Canakinumab ... congestive heart failure due to coronary artery disease ...

This study is being carried out to see if a new medicine, ziltivekimab, can be used to treat people living with heart failure and inflammation.

5 авг. 2021 г. · ... disease. Other data implicate the IL-1β to IL-6 pathway in congestive heart failure and acute coronary ischaemia. Despite this promise ...

Medical conditions - cardiovascular: · Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation ...

15 июн. 2021 г. · 1 - Effects of ziltivekimab versus placebo on cardiovascular ... • Number of hospitalisations for heart failure or urgent heart failure visit.

29 мая 2023 г. · Despite optimal treatment, a residual inflammatory risk often remains in patients with atherosclerotic cardiovascular disease.